Myasthenia Gravis: Treatment by Implantation of Desoxycorticosterone Acetate Pellets

The more recent development of endocrine chemistry with the manufacture of synthetic, relatively insoluble, products bids fair to become an excellent way of treating chronic endocrine deficiencies. The advantages of this form of treatment are many and obvious. I have recently treated a patient with a severe fulminating form of myasthenia gravis by the subcutaneous implantation of desoxycorticosterone acetate pellets. REPORT OF CASE M. G., a physician aged 32, complained Oct. 6, 1939, of severe dyspnea and rapid fatigability. The following is a report of his illness as written out by himself: "The onset of the disease was insidious but rapid. There were no prodromal signs or symptoms of any infectious process. "Dyspnea with the slightest exertion and fatigability with weakness were the major complaints. These were rapidly progressive over a period of seven days to the point of orthopnea and prostrating fatigue with but small effort. The patient could